Focus Partners Advisor Solutions LLC Acquires New Position in United Therapeutics Corporation $UTHR

Focus Partners Advisor Solutions LLC acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,467 shares of the biotechnology company’s stock, valued at approximately $795,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Leuthold Group LLC grew its holdings in United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares during the last quarter. UBS Group AG increased its position in shares of United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after buying an additional 70,445 shares in the last quarter. Nicholas Investment Partners LP raised its stake in shares of United Therapeutics by 478.5% during the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after buying an additional 3,766 shares during the last quarter. M&T Bank Corp raised its stake in shares of United Therapeutics by 171.6% during the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock worth $1,531,000 after buying an additional 1,985 shares during the last quarter. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of United Therapeutics in the 4th quarter worth about $633,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $564.11, for a total value of $5,641,100.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,648,140.36. This represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $565.98, for a total transaction of $5,376,810.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $22,929,547.74. This represents a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 452,575 shares of company stock valued at $246,248,389 in the last three months. 8.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently commented on UTHR. Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Royal Bank Of Canada cut their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Stock Up 1.8%

NASDAQ UTHR opened at $508.48 on Tuesday. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The business has a fifty day moving average of $535.22 and a 200-day moving average of $536.38. The stock has a market cap of $21.81 billion, a price-to-earnings ratio of 18.19, a price-to-earnings-growth ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $6.41 earnings per share. As a group, analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.